"The U.S. Food and Drug Administration today warned five eye care providers to stop the misleading advertising and promotion of refractive lasers used in eye surgery procedures such as LASIK. The FDA found that the providers’ advertisements "...
BETAXON™ (levobetaxolol hydrochloride ophthalmic suspension) 0.5% is indicated for lowering intraocular pressure in patients with chronic open-angle glaucoma or ocular hypertension.
DOSAGE AND ADMINISTRATION
The recommended dose is one drop of BETAXON™ (levobetaxolol hydrochloride ophthalmic suspension) 0.5% in the affected eye(s) twice daily. In some patients, the intraocular pressure lowering responses to BETAXON (levobetaxolol hydrochloride ophthalmic suspension) TM Ophthalmic Suspension may require a few weeks to stabilize. As with any new medication, careful monitoring of patients is advised. The concomitant use of two topical beta-adrenergic agents is not recommended.
Dosage Forms And Strengths
Bottle filled with 5, 10, and 15 mL of 0.5% sterile ophthalmic suspension.
Storage And Handling
BETAXON™ (levobetaxolol hydrochloride ophthalmic suspension) 0.5% is supplied as follows: 5, 10 and 15 mL in a clear LDPE plastic ophthalmic DROP-TAINER® dispenser and a yellow polypropylene screw cap.
5 mL: NDC 0065-0239-05
10 mL: NDC 0065-0239-10
15 mL: NDC 0065-0239-15
Store upright at 39°to 77°F (4°to 25°C).
Protect from Light.
Shake well before using.
Alcon Laboratories, Inc., Fort Worth, Texas 76134 USAThis monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 3/30/2010
Additional Betaxon Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get breaking medical news.